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Abstract
Osteoblast and adipocyte are derived from common mesenchymal progenitor cells. The bone loss of osteoporosis
is associated with altered progenitor differentiation from an osteoblastic to an adipocytic lineage. In this study, a
comparative analysis of gene expression profiling using cDNA microarray and realtime-PCR indicated that Zinc
finger protein 467 (Zfp467) involved in adipocyte and osteoblast differentiation of cultured adipose derived stem
cells (ADSCs). Our results showed that RNA interference for Zfp467 in ADSCs inhibited adipocyte formation and
stimulated osteoblast commitment. The mRNA levels of osteogenic and adipogenic markers in ADSCs were
regulated by si-Zfp467. Zfp467 RNAi in ADSCs could restore bone function and structure in an ovariectomized
(OVX)-induced osteoporotic mouse model. Thus Zfp467 play an important role in ADSCs differentiation to
adipocyte and osteoblast. This has relevance to therapeutic interventions in osteoporosis, including si-Zfp467-based
therapies currently available, and may be of relevance for the use of adipose-derived stem cells for tissue
engineering.
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Introduction
A d u l tb o n em a s si sm a i n t a i n e db ya ne x q u i s i t eb a l a n c e
between bone formation by osteoblasts and bone resorp-
tion by osteoclasts [1]. Disruption of this delicate equili-
brium can lead to osteoporosis (OP), a multifactorial,
age-related metabolic bone disease characterized by
reduction in bone mass, bone tissue microarchitectural
deterioration, and increased fracture risk [2,3].
A variety of risk factors have been associated with
osteoporosis, with emerging evidence suggesting a close
association between bone aging, disease, and stem/pro-
genitor cell defects [4,5]. Numerous animal and human
studies have examined the links between mesenchymal
or osteoprogenitor cell properties, aging, and osteopenia;
however, many results to date have been contradictory
and confusing.
Interpreting the results of these studies is further
complicated by variations in the cell source site,
isolation procedures, culture conditions, assay condi-
tions, metrics, and developmental time-points being
evaluated. The clearest trends are observed in murine
osteoporosis/osteopenia models, including SAMP6 [6,7]
and aged C57BL/6 [8] mice, which exhibit low bone
mass and/or bone material and mechanical defects
accompanied by altered mesenchymal progenitor prop-
erties (i.e., reduced numbers, proliferative capacity, or
osteogenic differentiation capacity).
There are emerging evidences linking osteoporosis and
stem cell defects, including osteoblast-progenitors
(mesenchymal stem cells, MSCs) residing in the bone
marrow [9], so it has been hypothesized that such cells
from in vitro culture might be infused back to osteope-
nic subjects in order to replenish their stem cell pool,
which would result in a positive bone balance and ulti-
mately the regeneration of the osteopenic skeleton.
Mesenchymal stem cells, the precursor cells of adipo-
cytes and osteoblasts [10], are found to play an impor-
tant role in bone physiology and partly participate in the
pathophysiology of osteoporosis. Indeed, in postmeno-
pausal women who suffered from osteoporosis, MSCs
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lower abilities to differentiate into osteogenic lineage
than those from premenopausal women [11]. The
increased volume of adipose tissue was also found in the
bone marrow of postmenopausal women, implying the
enhancement of MSCs’ differentiation into adipocytes
[12]. Additionally, because of increased cytokines from
stromal cells and osteoblasts that regulated osteoclast
generation due to estrogen loss, the number of osteo-
clasts increased and caused the elevated bone resorption
[13].
Another emerging stem cell for treatment osteoporosis
of is adipose-derived stem cells (ADSCs). The main ben-
efits of ADSCs in therapeutic applications, as compared
with bone marrow-derived MSCs, are that adipose tissue
is readily accessible and relatively abundant, and the
stem cell population can be easily harvested by simple
methods, such as lipoaspiration or surgical resection,
and can be rapidly expanded ex vivo [14]. ADSCs have
also been shown to support differentiation of hemato-
poietic progenitors into myeloid and B lymphoid cells
[15]. ADSCs-derived cellular therapy has been investi-
gated with respect to a wide variety of human diseases,
such as skeletal muscle disorders, cardiovascular disor-
ders, and diabetes mellitus, and in bioengineering for
tissue regeneration [16]. Additive support of ADSCs in
tissue repair and regeneration has been reported to
include differentiation into a proper cell lineage and
paracrine mechanisms mediated by secreted cytokines
and growth factors [17].
In this study, we characterize the initiation and adipo-
cyte and osteoblast differentiation of cultured ADSCs at
the cellular level. We hypothesized that Zinc finger pro-
tein 467 (Zfp467), a novel regulator of osteoblast and
adipocyte commitment [18], would lead to adipocyte dif-
ferentiation of ADSCs. We predicted that suppression of
this factor by RNA interfere would mediate the expres-
sions of specific osteogenic and adipogenic genes and
alleviate ovariectomized (OVX)-induced osteoclasts for-
mation and bone destruction.
Materials and methods
Isolation and culture of ADSCs
Mouse abdominal adipose tissues were obtained under
approval from the Animal Research Guidelines of Shang
Jiao Tong University School of Medicine. The lipoaspi-
rate was incubated with collagenase type I solution
(Worthington Biochemical, Lakewood, NJ) for 1 h at 37°
C, and filtered through 250 μm filters. Following centri-
fugation, the stromal vascular fraction was resuspended
in DMEM (HyClone, Logan, UT) supplemented with
10% FBS (HyClone), 100 U/ml penicillin, and 100 μg/ml
streptomycin. ADSCs were cultured under a humidified
atmosphere of 5% CO2 at 37°C for long-term culture in
vitro and were capable of differentiating into adipocytes
and osteogenic cells under specific induction [19].
Differentiation in cultured ADSCs was monitored
including oil red O staining of lipid droplets in terminal
adipocyte differentiation and von Kossa staining of cal-
cium deposition in the extracellular matrix in terminal
osteoblast differentiation.
Vector construction
The lentiviral vector enco d i n gZ f p 4 6 7s h R N A 1( K D 1 )
(5’-TTAGCTCATGAACGCAGACC-3’)a n ds h R N A 2
(KD2) (5’-AGTCGTACCACAGAACTGTC-3’)u n d e r
the human H1 RNA polymerase III promoter has been
described [20]. A si-Zfp467 expression unit was gener-
ated by inserting hybridized oligo DNAs into pBShH1
plasmid DNA. After sequence confirmation, two si-
Zfp467 expression units were excised from the pBShH1
plasmid DNA by XbaI and XhoI digestion and inserted
into XbaI/XhoI sites of the FG12 lentiviral vector. A
scrambled si-RNA was used as a control.
Virus production and titration
We generated lentiviral vector stocks using an HIV-1-
based reporter virus, packaging plasmid pCMV
R8.2ΔVpr and the VSV-G envelope protein-coding plas-
mid by calcium phosphate-mediated transient transfec-
tion of 293T cells. Culture supernatants were harvested
on 2 days after transfection. Lentiviral vector particles
were concentrated 300-fold by ultracentrifugation. Con-
centrated virus stocks at a multiplicity of infection of 10
were titrated on 293 T-cells based on EGFP expression.
Transfection and transplantion of cells
ADSCs were transduced ex vivo with the VSV-G pseu-
dotyped shRNA vector at a multiplicity of infection of
once per day for 2 days with gentamicin. Transduction
efficiency was analyzed by quantifying EGFP expression
by flow cytometry 48 h after transduction.
Detection of ADSCs after intravenous injection
After eight-week-old female ddY mice had been ovariec-
tomized, ADSCs (2 × 10
6 cells/mouse) labeled with iron
oxide (Ferridex, Berlex Laboratories Inc, Wayne, NJ)
were injected into OVX mice via tail vein on postopera-
tive day 4 and sacrificed at day 24 after injection. Bone
tissues were fixed and decalcified with EDTA solution.
After washing, paraffin-embedded specimens were sec-
tioned, deparaffinized, incubated with 1% potassium fer-
rocyanide in 1% HCl for 30 min, and counterstained with
nuclear fast red. Six animals were included in each group.
Real-time quantitative, Western blotting and ELISA
For detection of mRNA level, total RNA was isolated
with TRIzol (Invitrogen, Carlsbad, CA), according to the
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was reverse transcribed using Moloney Murine Leuke-
mia Virus Reverse Transcriptase (Promega, Madison,
WI) with oligo dT at 42°C for 1 h. Detailed information
on PCR, including primer sequences and cycles, is pro-
vided in Table 1.
For Western blotting, cells were lysed by addition of
lysis buffer containing 20 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM
EDTA, 0.1% SDS, protease inhibitors (Complete tablets,
Roche Molecular Biochemicals, Mannheim, Germany), 1
mM Na3VO4, and 1 mM NaF. Proteins were separated
by 10% SDS-PAGE, transferred to a nitrocellulose mem-
brane, and probed with Zfp467 antibody (R&D Systems
Inc., Minneapolis).
Urine deoxypyridinoline was assayed by competitive
enzyme immunoassay using the MicroVue DPD EIA kit
(Quidel Corporation, Santa Clara, CA).
Flow cytometry
ADSCs were harvested by trypsinization and centrifuga-
tion, washed twice with cold PBS, and fixed with cold
75% ethanol at 4°C overnight. The fixed cells were col-
lected, washed twice with PBS and suspended in PBS.
Flow Cytometry was using to array cultured ADSCs at
day 7 with FITC-conjugated anti-CD29, FITC-conju-
gated anti-CD44, PE-conjugated anti-CD45 and PE-con-
jugated anti-HLA-DR antibody (Abcom Inc., Cambridge,
Massachusetts), respectively.
Gene expression profiling analysis using cDNA microarray
The cDNAs retrotranscribed from an equal amount of
mRNA from control (ADSCs at day 0), adipocyte and
osteoblast derived from ADSCs at day 14, were labeled
with Cy3 and Cy5 fluorescence as probes, respectively.
Fluorescence intensity was measured for each gene spot.
After background subtraction and the whole-chip data
normalization, the ratios of gene expression differences
between these sets of samples were obtained. BioStar H-
40s microarray consisted of 4096 novel or known genes
including control system and effective genes (provided
by Biostar Genechip Inc). The control system consists of
96 housekeeping genes as loading control; 16 plant
genes, and spotting solution (without DNA, 16 spots) as
negative control spots in the array. The chips were
scanned with a ScanArray 4000. The acquired images
were analyzed using GenePix Pro 3.0 software.
Microcomputed tomography and histological analysis of
bone
At o t a lo f2×1 0
6 cells were injected into sham-oper-
ated or ovariectomized female ddY mice (8-week-old,
Central lab animal, Korea) via tail vein on postoperative
day 4 and sacrificed at day 24 after injection (n = 6 per
group). Microcomputed tomography (μCT) and histolo-
gical analysis were performed, as reported previously
[7,21]. Trabecular morphometry within the proximal
tibia was quantified using high resolution microcom-
puted tomography (μCT, Skyscan 1076 μCT, Aartselaar,
Table 1 Nucleotide sequences of 10 primers for qRT-PCR.
Gene Primer Sequence (5’ -3 ’) Melting temperature
(°C)
Product size (bp)
b-actin Forward 5’-GTGGAGTGCCCAAGCACCA- 3’ 52 213
Reversed 5’-CTCTAATGTCACGACGATTTC-3’
Adiponectin Forward 5’-AGGAATTCTACTGCCGTCGA-3’ 55 179
Reversed 5’-TCAAGGCGAGCTCGTATTTGA-3
AIP Forward 5’-GCTAGCAAACCACCTAAGTA-3 54 207
Reversed 5’-GTGGTCCAGAACATAGTAGA-3
Zfp467 Forward 5’-CACGTGACACCTACCAAGTA-3 55 186
Reversed 5’-CCGTAACAGGTATGAGTAGA-3
OCN Forward 5’-GCCCAGCTGTAACCACGATA-3 56 126
Reversed 5’-CAGGTCCATAAGGTAGTAGA-3
OPN Forward 5’-GCATGCTACACCAACCAGTA-3 52 198
Reversed 5’-CAGAAGTGGTGTACAGTAGA-3
COL I Forward 5’-GCAGCCCCATAGACGCCGTA-3 51 171
Reversed 5’-CAGAGGTCATCCACCAATAGA-3
BSP Forward 5’-GCAGAGTAGTACTGCAGGTA-3 55 190
Reversed 5’-CAGAGGTGTCCATAAGTAGA-3
LPL Forward 5’-GCGAGTGTAGCTCAGCCGTA-3 53 185
Reversed 5’-CAGGTCCATAGAGGTAGTAGA-3
PPARg Forward 5’-GTAGAGTGGCACAGTGGGTA-3’ 52 313
Reversed 5’-TTACTTGCCATCAAGATTGTC-3’
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bone volume/total volume (BV/TV), trabecular number
(Tb.N), and bone mineral density (BMD) were assessed.
For analysis of bone formation, mice were injected with
calcein (10 mg/kg) on postoperative day 14 and day 21
and were sacrificed at postoperative day 24.
OC number (no.) per bone surface (NOc/BS) and OB
number per bone surface (NOb/BS) were analyzed by
tartrate-resistant acid phosphatase (TRAP) staining on
the 7-mm thick sagittal sections, as described previously
[22]. TRAP positive cells containing one or more nuclei
and sitting on the surface of the trabeculae were defined
as osteoclasts. One section per animal was analyzed for
these parameters.
Statistical analysis
The results were expressed as mean ± SD. The data
were treated by Student’s t test to determine statistical
significance. We used nonparametric tests (Mann-Whit-
ney test), if appropriate, to compare differences. P <
0.05 was considered statistically significant. Statistical
analysis was performed using SPSS 12.0 software.
Figure 1 Microphotographs and Flow Cytometry of cultured ADSCs. (A-D) Microphotographs of cultured ADSCs at day 1, 3, 5 and 7,
respectively. Bar scale = 20 μm. Flow Cytometry was using to array cultured ADSCs at day 7 with FITC-conjugated anti-CD29 (E), FITC-
conjugated anti-CD44 (F), PE-conjugated anti-CD45 (G) and PE-conjugated anti-HLA-DR antibody (H), respectively.
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ADSC morphology and characteristics
ADSCs were obtained from the abdomens of 3- to 6-
week-old mice and primary ADSCs displayed typical
fibroblast-like morphology and were maintained for
long-term culture in vitro (Figure 1A-D), and were cap-
able of differentiating into adipocytes (Figure 2A-C) and
osteogenic cells (Figure 2D-F) under specific induction
[19]. Cell surface marker expression by ADSCs isolated
from human adipose tissue was characterized. Flow
cytometric analysis of ADSCs revealed that high levels
of MSC-related CD29 and CD44 were expressed (Figure
1E, F); however, hematopoiesis-related antigens CD45
and immunogenicity markers HLA-DR were not
expressed (Figure 1G, H).
In additional, the ability of ADSCs to differentiate into
adipocyte and osteoblast lineages at passage 3 was
experimentally confirmed by Oil red O staining (Figure
2B), von Kossa staining (Figure 2E) and the mRNA
levels of specific adipogenic (adiponectin) (Figure 2C)
and osteogenic (alkaline phosphatase) markers (Figure
2F), respectively. These results showed that ADSCs have
multilineage potential and characteristics of MSCs.
Gene expression profiling changes of adipocyte and
osteoblast differentiation from ADSCs
N e x t ,w es t u d i e dt h ed i f f e r e n c eo fg e n ee x p r e s s i o np r o -
file changes between adipocyte and osteoblast differen-
tiation from ADSCs at day 14 and to screen the
critical genes in the early differentiation stage by
Figure 2 Adipocyte and osteoblast differentiation of cultured ADSCs. Microphotographs of ADSCs differentiated into adipocytes (A) and
osteoblasts (D) at day 14. Bar scale = 50 μm. Differentiation in cultured ADSCs was monitored including oil red O staining of lipid droplets in
terminal adipocyte differentiation (B) and von Kossa staining of calcium deposition in the extracellular matrix in terminal osteoblast
differentiation (E). The qRT-PCR analysis of mRNA levels of specific adipogenic (adiponectin) (C) and osteogenic (alkaline phosphatase) markers (F)
at day 7 and day 14 of differentiation as compared to day 0. The data are representative of three independent experiments.
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with Cy3 and Cy5 fluorescent signal values displayed a
quite disperses pattern in distribution. Most of the
spots gathered around a 45° line, in which red spots
represented the area where the signal intensities varied
between 0.5 to 2-fold compared with those of the con-
trol. Some yellow spots distributed beyond or far from
45° line indicated the existence of abnormal gene
expressions between adipocyte and osteoblast derived
from ADSCs at day 14. Their signal intensities were 2
times more than that of the control (Figure 3A-C). As
shown in Figure 3D-F, 298 genes were screened out
that exhibited different expressions between ADSCs,
adipocyte and osteoblast derived from ADSCs, there
were 175 up-regulated and 123 down-regulated genes
in the gene expression profiles of ADSCs which was 2
times of that in adipocyte and osteoblast derived from
ADSCs.
Zfp467 knockdown by shRNA-expressing vectors
We then choose Zfp467, a novel regulator of osteoblast
and adipocyte commitment [18], to further study the
molecule mechanism of ADSCs differentiation. The
mRNA and protein levels of Zfp467 in adipocyte and
osteoblast derived from ADSCs (Day 14) and control
(ADSCs, Day 0) were measured using qRT-PCR and
Western blot analysis, respectively. The results showed
that the mRNA levels of Zfp467 in adipocyte derived
from ADSCs was notably increased when compared
with that in the control, however the mRNA levels of
Zfp467 was significantly decrease after ADSCs differen-
tiation to osteoblast (Figure 4A). The change of Zfp467
protein levels showed to be the same on the mRNA
levels of Zfp467 in three groups (Figure 4B).
We then created a lentiviral vector encoding Zfp467
shRNA for long-term expressing Zfp467 siRNA to
knockdown Zfp467 gene expression. We used two
Figure 3 Gene expression profiling of ADSCs. The Gene expression profiling of adipocyte and osteoblast derived from ADSCs at day 14 and
undifferentiated ADSCs (Day 0) were measured using cDNA microarray. The scatter plots that were plotted with Cy3 and Cy5 fluorescent signal
values displayed a quite disperses pattern in distribution (A-C). Some yellow spots distributed beyond or far from 45°line indicated the existence
of abnormal gene expressions in three groups (D-F).
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termed as Zfp467 shRNA-1 (KD1) and Zfp467 shRNA-2
(KD1). Control cells were transfected with lentiviral vec-
tor expressing scrambled siRNA. Zfp467 shRNA-1 and
shRNA-2 dramatically reduced Zfp467 expression at
both mRNA (Figure 4C) and protein levels (Figure 4D).
The inhibition rate of Zfp467 shRNA-1 and Zfp467
shRNA-2 were 64.4% and 83.6%, respectively in ADSCs
compared with the mock and control group at mRNA
levels (Figure 4C). However, shRNA-2 caused more pro-
found reduction of Zfp467 gene expression when com-
pared to shRNA-1, reflecting a sequence-specific effect
of the siRNA (Figure 4C, D).
Effect of Zfp467 shRNA on adipocytes and osteoblasts
differentiation
As mentioned above, in two representative subclones,
Zfp467 shRNA-2 caused more profound reduction of
Zfp467 gene expression when compared to shRNA-1.
Hereafter, we mainly used the Zfp467 shRNA-2 subline
for further analysis. The expressions of specific osteo-
genic and adipogenic genes were evaluated by real-time
RT-PCR at 0, 3, 7 and 14 days post-transduction. Our
results indicated that specific osteogenic marker Osteo-
calcin (OCN), Osteopontin (OPN), Collagen I (COL I)
and bone sialoprotein (BSP) were up-regulated in si-
Zfp467 transduced cells (Figure 5A-D). Specific adipo-
genic marker lipoprotein lipase (LPL) and peroxisome
proliferator-activated receptor gamma (PPARg)w e r e
down-regulated in si-Zfp467 transduced cells (Figure
5E-F). The statistical analysis showed that the plasmid
Zfp467 shRNA could have significant inhibitive effects
on the mRNA levels of specific adipogenic gene at day 7
a n d1 4w h e nc o m p a r e dw i t ht h a to fa d i p o g e n i cg e n ea t
day 0 and 3 (p < 0.05 and p < 0.01, respectively) (Figure
5A-D), however, RNA interfere of Zfp467 significantly
enhanced the mRNA levels of specific osteogenic gene
at day 7 and 14 when compared with that of osteogenic
Figure 4 The mRNA and protein levels of Zfp467 in cultured adipocyte, osteoblast and undifferentiated ADSCs. The mRNA and protein
levels of Zfp467 in adipocyte and osteoblast derived from ADSCs at day 14 and undifferentiated ADSCs (Day 0) were measured using qRT-PCR
(A) and Western blot analysis (B). The data are representative of three independent experiments. The two si-Zfp467 vector (pSilencer4.1-si-Zfp467
with neomycin resistance), which produces specific siRNA (Zfp467-KD1 and -KD2) were used in the experiment. Scrambled siRNA was used as a
control for siRNA-Zfp467. The efficiencies of Zfp467 RNAi in ADSCs were evaluated using qRT-PCR (C) and Western blot analysis (D).
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(Figure 5E-F), which suggested Zfp467 involved in the
ADSCs differentiated into adipocytes and osteoblasts.
Effects of systemic transplantation of ADSCs on OVX-
induced bone loss
We performed μCT analysis to determine the impact of
ADSCs and Zfp467 on OVX-induced osteoporotic mice.
Systemic transplantation of ADSCs with si-Zfp467 into
OVX mice prevented OVX-induced bone loss in mice.
When compared with OVX or ADSCs (with scrambled
siRNA)-transplanted OVX mice, bone loss indices,
including bone volume fraction, trabecular number, and
bone mineral density in si-Zfp467-ADSCs transplanted
OVX mice were restored to normal (the level of sham-
operated mice) (Figure 6A-C).
The recovery effect of ADSCs with si-Zfp467 on bone
loss was confirmed by measurement of the
Figure 5 The expressions of specific osteogenic and adipogenic genes. The expressions of specific osteogenic and adipogenic genes in
ADSCs were evaluated by real-time RT-PCR at 0, 3, 7 and 14 days after siRNA-Zfp467 transduction. Specific osteogenic marker Osteocalcin (OCN)
(A), Osteopontin (OPN) (B), Collagen I (COL I) (C) and bone sialoprotein (BSP) (D) were up-regulated in si-Zfp467 transduced cells. Specific
adipogenic marker lipoprotein lipase (LPL) and peroxisome proliferator-activated receptor gamma (PPARg) were down-regulated in si-Zfp467
transduced cells (Mean ± SEM, n = 3). * p < 0.05 vs. control group; ** p < 0.01 vs. control group.
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marker of bone resorption. Compared with OVX or
ADSCs (with scrambled siRNA)-transplanted OVX
mice, a significantly lower level of urinary deoxypyridi-
noline (DPD) was exhibited by si-Zfp467-ADSCs trans-
planted OVX mice (Figure 6D). Mineral apposition rate
and bone formation rate, as measured by calcein label-
based analysis, were restored to the level of sham-oper-
ated mice in si-Zfp467-ADSCs transplanted OVX mice.
Of particular interest, histologic analysis showed that
the numbers of osteoblasts adhering to trabecular bone
surfaces were significantly increased in si-Zfp467-
ADSCs transplanted OVX mice compared with OVX or
ADSCs (with scrambled siRNA)-transplanted OVX mice
(Figure 6E) (p < 0.01) and the numbers of TRAP-posi-
tive osteoclasts evidently decreased, which suggested
that systemic transplantation of si-Zfp467-ADSCs in
OVX mice might affect proliferation or differentiation of
osteoblasts and osteoclasts. From these data, we con-
firmed that Zfp467 plays an important role in ADSCs to
alleviate OVX-induced osteoporosis through regulating
ADSCs differentiation to adipocyte and osteoblast.
Figure 6 Effects of systemic transplantation of ADSCs on OVX-induced osteoclasts formation and bone destruction. Tibiae from sham-
operated (sham) and OVX (OVX, OVX + Scrambled siRNA and OVX + si-Zfp467) mice were examined by μCT. 3D reconstruction of tibiae
revealed that bone mass in OVX mice treated with si-Zfp467 ADSCs (OVX + si-Zfp467) significantly increased when compared with that in OVX
or ADSCs (with scrambled siRNA) transplanted OVX mice. (A-C) Histograms represent the 3D trabecular structural parameters in tibiae: bone
volume fraction (BV/TV), trabecular number (Tb.N), and bone mineral densities (BMD). (D) The levels of DPD in four groups were assayed by
competitive enzyme immunoassay using the MicroVue DPD EIA kit. (E) OC number (no.) per bone surface (NOc/BS) was using to indicate
quantification of OC cells. (F) OB number per bone surface (NOb/BS) was using to indicate quantification of OB cells. *P < 0.01, **P < 0.05. Data
represent mean ± SD. n = 6.
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In this study, we showed that ADSCs-based therapy via
systemic transplantation could be effective in alleviating
OVX-induced osteoporosis by a mechanism predomi-
nantly mediated through suppression of Zfp467.
Osteoporosis is a prevalent bone disease that is charac-
terized by loss of bone mass and strength, leading to fragi-
l i t yf r a c t u r e[ 2 3 ] .O s t e o b l a sts, which are derived from
mesenchymal stem cells, are ultimately responsible for
bone formation; osteoclasts are derived from hematopoie-
tic cells and are capable of resorbing bone. During adult
life, bone is continuously remodeled by orchestrated
cross-talk between osteoblasts and osteoclasts [24], and an
imbalance in their function results in decreased bone qual-
ity, most commonly represented by the osteoporotic phe-
notype. A relatively higher bone resorption activity by
osteoclasts than bone formation activity by osteoblasts
leads to bone loss. High-turnover and low-turnover osteo-
porotic phenomena are known to be achieved by excessive
bone resorption and reduced bone formation during bone
remodeling, respectively [25].
Recent progress in stem cell biology has provided a
promising strategy for treatment of osteoporosis. Thera-
peutic potential for bone regeneration by systemic trans-
plantation of genetically manipulated MSCs
coexpressing CXCR4 and Runx2 in glucocorticoid-
induced osteoporotic mice has been recently suggested
[26]. Lee K, et al. showed that hASC-based therapy via
systemic transplantation could be effective in bone
repair by a mechanism predominantly mediated through
secretion of paracrine factors by hADSCs [27].
Considering the fact that the pathogenetic mechan-
isms underlying osteoporosis cover multiple sets of
dynamic parameters, a systemic approach using stem
cell transplantation is attractive for treatment of osteo-
porosis. Our in vivo results revealed that OVX-induced
bone loss was restored by systemic transplantation of
ADSCs into recipient OVX mice. We further showed
that si-Zfp467-ADSCs-injected OVX mice exhibited an
increase in the number of both osteoblasts and osteo-
clasts. This could be explained by the balance between
bone resorption and bone formation. The levels of bone
resorption by osteoclasts did not exceed those of bone
formation by osteoblasts, resulting in a net increase of
bone mass. These findings indicate that RNAi of Zfp467
in ADSCs can rescue estrogen deficiency-induced bone
loss by simultaneous stimulation of osteoblast-mediated
bone formation and osteoclast-mediated bone resorption
in recipient OVX mice.
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